Schrodinger falls after ending blood cancer therapy development on patient deaths

** Shares of drug developer Schrodinger slump 19.1% to $16.05 premarket** Company says it will stop the development of its experimental therapy, SGR-2921, for two types of blood cancer after it was considered to have contributed to two patient deaths in an early-stage study** "Patient safety is our first priority," SDGR's medical chief says. "While disappointing given the early clinical activity observed, we believe this is the right decision for patients"** Up to last close, shares up 2.9% YTD